Xolair 300 MG/2 ML syringe 2ML
Ended Awarded
- Contract number
- SPE2DB26FDD86
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,721
Award facts
- Contract value 100% obligated
- $3,720.98 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $3,720.98 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml syringes. The award, issued on October 30, 2025, utilizes a firm fixed-price delivery order structure with an ultimate completion date of November 21, 2025. This delivery order was issued without a set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. The place of performance is Park Ridge, Illinois, where DMS Pharmaceutical Group maintains its operations and serves as a critical supplier within the federal pharmaceutical supply chain.
This delivery order is issued under DMS Pharmaceutical Group's indefinite delivery contract (IDC) within the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support recurring medical supply needs of military healthcare facilities worldwide. The underlying IDC, designated SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. DMS Pharmaceutical Group's established performance across numerous delivery orders for diverse pharmaceutical products, including biologics, specialty pharmaceuticals, and routine medications, positions the company as a key regional prime vendor contractor supporting Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DB26FDD86?
SPE2DB26FDD86 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 30, 2025.
How much is contract SPE2DB26FDD86 worth?
The government has obligated $3,721 on SPE2DB26FDD86.
Is contract SPE2DB26FDD86 an order under another contract?
Yes. SPE2DB26FDD86 is a delivery order under SPE2DB22D9239, an indefinite delivery contract.
Was contract SPE2DB26FDD86 competed?
The extent of competition for SPE2DB26FDD86 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award